Pseudobufarenogin

CAS No. 17008-69-4

Pseudobufarenogin( ψ-Bufarenogin )

Catalog No. M23765 CAS No. 17008-69-4

Pseudobufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 215 In Stock
5MG 188 In Stock
10MG 282 In Stock
25MG 489 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pseudobufarenogin
  • Note
    Research use only, not for human use.
  • Brief Description
    Pseudobufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
  • Description
    Pseudobufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ψ-Bufarenogin
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    17008-69-4
  • Formula Weight
    416.51
  • Molecular Formula
    C24H30O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:Soluble
  • SMILES
    C[C@]([C@H](CC1)C(C=C2)=COC2=O)([C@H](C([C@@H]([C@H]2CC3)[C@@](C)(CC4)[C@H]3C[C@H]4O)=O)O)[C@@]12O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ding J, et al. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. Oncotarget. 2015 May 10;6(13):11627-39.
molnova catalog
related products
  • EGFRvIII peptide PEP...

    PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.

  • (Lys8,Lys9)-Neuroten...

    [Lys8, Lys9]-Neurotensin (8-13) (JMV438), a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2, with Ki values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively.

  • BPP 5a

    Bradykinin potentiator-5 is a peptide inflammatory mediator, causes blood vessels to dilate (enlarge), and therefore causes blood pressure to fall.